Extrapulmonary neoplasms in lung cancer screening

Research output: Contribution to journalReview article

Myrna C.B. Godoy, Charles S. White, Jeremy J. Erasmus, Carol C. Wu, Mylene T. Truong, Reginald F. Munden, Caroline Chiles

A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors. Considering the fact that 22.3% of the certified deaths in the computed tomography (CT) arm of the NLST trial were due to extrapulmonary malignancies, compared to 22.9% of deaths from lung cancer, it is possible that early diagnosis and treatment of clinically significant incidental findings may further decrease morbidity and mortality in screening participants. In this article we review prevalence, clinical relevance and management of incidentally detected extrapulmonary malignancies.

Original languageEnglish (US)
Pages (from-to)368-375
Number of pages8
JournalTranslational Lung Cancer Research
Volume7
Issue number3
DOIs
StatePublished - Jun 1 2018

Altmetrics

Cite this

Standard

Extrapulmonary neoplasms in lung cancer screening. / Godoy, Myrna C.B.; White, Charles S.; Erasmus, Jeremy J.; Wu, Carol C.; Truong, Mylene T.; Munden, Reginald F.; Chiles, Caroline.

In: Translational Lung Cancer Research, Vol. 7, No. 3, 01.06.2018, p. 368-375.

Research output: Contribution to journalReview article

Harvard

Godoy, MCB, White, CS, Erasmus, JJ, Wu, CC, Truong, MT, Munden, RF & Chiles, C 2018, 'Extrapulmonary neoplasms in lung cancer screening' Translational Lung Cancer Research, vol. 7, no. 3, pp. 368-375. DOI: 10.21037/tlcr.2018.06.05

APA

Godoy, M. C. B., White, C. S., Erasmus, J. J., Wu, C. C., Truong, M. T., Munden, R. F., & Chiles, C. (2018). Extrapulmonary neoplasms in lung cancer screening. DOI: 10.21037/tlcr.2018.06.05

Vancouver

Godoy MCB, White CS, Erasmus JJ, Wu CC, Truong MT, Munden RF et al. Extrapulmonary neoplasms in lung cancer screening. Translational Lung Cancer Research. 2018 Jun 1;7(3):368-375. Available from, DOI: 10.21037/tlcr.2018.06.05

Author

Godoy, Myrna C.B. ; White, Charles S. ; Erasmus, Jeremy J. ; Wu, Carol C. ; Truong, Mylene T. ; Munden, Reginald F. ; Chiles, Caroline. / Extrapulmonary neoplasms in lung cancer screening. In: Translational Lung Cancer Research. 2018 ; Vol. 7, No. 3. pp. 368-375

BibTeX

@article{8833edf7f8c2411c851380a59f6d80a8,
title = "Extrapulmonary neoplasms in lung cancer screening",
abstract = "A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors. Considering the fact that 22.3{\%} of the certified deaths in the computed tomography (CT) arm of the NLST trial were due to extrapulmonary malignancies, compared to 22.9{\%} of deaths from lung cancer, it is possible that early diagnosis and treatment of clinically significant incidental findings may further decrease morbidity and mortality in screening participants. In this article we review prevalence, clinical relevance and management of incidentally detected extrapulmonary malignancies.",
keywords = "Computed tomography (CT), Incidental findings (IFs), Low-dose computed tomography (LDCT), Lung cancer, Neoplasm, Screening",
author = "Godoy, {Myrna C.B.} and White, {Charles S.} and Erasmus, {Jeremy J.} and Wu, {Carol C.} and Truong, {Mylene T.} and Munden, {Reginald F.} and Caroline Chiles",
year = "2018",
month = "6",
day = "1",
doi = "10.21037/tlcr.2018.06.05",
language = "English (US)",
volume = "7",
pages = "368--375",
journal = "Translational Lung Cancer Research",
issn = "2218-6751",
publisher = "Society for Translational Medicine (STM)",
number = "3",

}

RIS

TY - JOUR

T1 - Extrapulmonary neoplasms in lung cancer screening

AU - Godoy,Myrna C.B.

AU - White,Charles S.

AU - Erasmus,Jeremy J.

AU - Wu,Carol C.

AU - Truong,Mylene T.

AU - Munden,Reginald F.

AU - Chiles,Caroline

PY - 2018/6/1

Y1 - 2018/6/1

N2 - A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors. Considering the fact that 22.3% of the certified deaths in the computed tomography (CT) arm of the NLST trial were due to extrapulmonary malignancies, compared to 22.9% of deaths from lung cancer, it is possible that early diagnosis and treatment of clinically significant incidental findings may further decrease morbidity and mortality in screening participants. In this article we review prevalence, clinical relevance and management of incidentally detected extrapulmonary malignancies.

AB - A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors. Considering the fact that 22.3% of the certified deaths in the computed tomography (CT) arm of the NLST trial were due to extrapulmonary malignancies, compared to 22.9% of deaths from lung cancer, it is possible that early diagnosis and treatment of clinically significant incidental findings may further decrease morbidity and mortality in screening participants. In this article we review prevalence, clinical relevance and management of incidentally detected extrapulmonary malignancies.

KW - Computed tomography (CT)

KW - Incidental findings (IFs)

KW - Low-dose computed tomography (LDCT)

KW - Lung cancer

KW - Neoplasm

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85048677174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048677174&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2018.06.05

DO - 10.21037/tlcr.2018.06.05

M3 - Review article

VL - 7

SP - 368

EP - 375

JO - Translational Lung Cancer Research

T2 - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2218-6751

IS - 3

ER -

ID: 39882297